Uncategorized

The untold side of the movie “Dallas Buyers Club”

The movie Dallas Buyers Club brings attention to a little-recognized part of the AIDS activist movement: the desperate struggle to provide anything that might treat the disease when no treatment was available. AL-721, Compound Q, Peptide T—buyers clubs formed around the country to bring in potential treatments, whether pharmaceutical or botanical, for both the virus …

The untold side of the movie “Dallas Buyers Club” Read More »

Activists Condemn Gilead for Exhorbitant Price of Their New Hepatitis C Drug

For Immediate Release December 9, 2013 Contact: Lynda Dee 410-332-1170 or lyndamdee@aol.com Fair Pricing Coalition Condemns Gilead Sciences on the High Price of New Hepatitis C Drug Sovaldi™, and Urges Rapid and Wide Dissemination of Support Program Details for Uninsured and Underinsured People Living with Hepatitis C The Fair Pricing Coalition (FPC) today condemned Gilead …

Activists Condemn Gilead for Exhorbitant Price of Their New Hepatitis C Drug Read More »

Briefing at Congress: The Changing Face of HIV/AIDS in America

Briefing:   The Changing Face of HIV/ AIDS in America September 18, 2013  Briefing: 9:30-10:30 a.m. Reception: 10:30-11 :30 a.m. US Congress Capitol Visitors Center, Room SVC 212 Hosted by: AIDS Community Research Initiative of America (ACRIA)  Services and Advocacy for GLBT Elders (SAGE)  National Hispanic Council on Aging Human Rights Campaign Gay Men’s Health Crisis …

Briefing at Congress: The Changing Face of HIV/AIDS in America Read More »

Once a Month HIV Medications – Cost Effectiveness

Long-acting antiretroviral (ARV) formulations, now in clinical development, could prolong survival in people with HIV, according to results of a modeling study [1]. But the benefit may hold true only in people with barriers to good adherence. Although long-acting antiretrovirals may not be cheap, the researchers determined they could be “a good value” when used …

Once a Month HIV Medications – Cost Effectiveness Read More »

HPV vaccine wears off quickly in HIV-positive women

Women with HIV probably need a booster shot of HPV vaccine within 2 years to maintain efficacy, according to a Canadian study of quadrivalent HPV vaccine (Gardasil) in 136 HIV-positive women. Antibody response to the vaccine is strong enough at 2 years to protect about 90% of HIV-negative women against HPV [human papillomavirus]. “But in …

HPV vaccine wears off quickly in HIV-positive women Read More »

What Can We Look Forward to in HIV Cure Research? Conversation With Research Advocate Richard Jefferys

This past March, the 20th Conference on Retroviruses and Opportunistic Infections (CROI) brought an unprecedented flurry of mainstream interest in potential HIV cure strategies. TheBodyPRO.com’s Nelson Vergel sat down with leading HIV cure research activist Richard Jefferys for an update on current important aspects, and controversies, in HIV cure research. Jefferys, who coordinates the Basic Science Vaccines …

What Can We Look Forward to in HIV Cure Research? Conversation With Research Advocate Richard Jefferys Read More »

ViiV goes for gold: US premium pricing may threaten dolutegravir use in Europe

On 12 August 2013, the FDA approved dolutegravir in the US. i-Base reported the news with an article linked to previous clinical trial results that noted not only the potential advantages but also some of the cautions.  One of the concerns was how the price, which didn’t accompany the original company press statement, would be …

ViiV goes for gold: US premium pricing may threaten dolutegravir use in Europe Read More »

Monthly or Quarterly Injectable HIV Antiretrovirals Are Safe and Effective in Early Study

GSK744, an investigational integrase inhibitor, and TMC278 LA (a long-acting, injectable form of the NNRTI rilpivirine [Edurant]) both showed safety and efficacy when administered in once-monthly or once-quarterly doses, according to a study presented at IAS 2013. There were no drug-related serious adverse events and all adverse events were either mild or moderate. The phase 1 …

Monthly or Quarterly Injectable HIV Antiretrovirals Are Safe and Effective in Early Study Read More »

The Future of HIV Treatment is Here: Once-a-Month Injections to Replace Daily Oral Medications

A combination of antiretroviral drugs in long-acting nanosuspension formulations achieved adequate blood levels and appeared safe in HIV negative study volunteers, offering the potential for a maintenance or PrEP option that could be taken once monthly, researchers reported at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur. While modern antiretroviral therapy is highly safe and …

The Future of HIV Treatment is Here: Once-a-Month Injections to Replace Daily Oral Medications Read More »

Calimmune Initiates HIV Stem Cell Study at Two California Research Sites

(Los Angeles, CA) — The HIV gene medicines company Calimmune announced today that the first patient has begun treatment in a Phase I/II clinical trial designed to determine whether a pioneering genetic medicine approach can help to protect individuals infected with HIV from the effects of the virus. The study, “Safety Study of a Dual …

Calimmune Initiates HIV Stem Cell Study at Two California Research Sites Read More »

Two More Patients Are Cured of HIV- And This Time With A Less Complex Regimen

“Both the surviving patients had been receiving prolonged antiretroviral therapy and received stem cell transplants with a reduced-intensity conditioning regimen of chemotherapy designed to eradicate the cancer and eliminate the existing bone marrow. In the case of the two patients under investigation, the conditioning regimen did not include radiotherapy and it did not eliminate the …

Two More Patients Are Cured of HIV- And This Time With A Less Complex Regimen Read More »